97631-87-3

Basic information

• Product Name: 4-bromophenyl 2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl ether
• Synonyms: 4-bromophenyl 2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl ether
• CAS NO: 97631-87-3
• Molecular Weight: 389.067
• Mol File: 97631-87-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-bromophenyl 2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl ether(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromophenyl 2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl ether(97631-87-3)
• EPA Substance Registry System: 4-bromophenyl 2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl ether(97631-87-3)

Safety Data

• Hazardous Substances Data: 97631-87-3(Hazardous Substances Data)

Upstream product

• 106-41-2 4-bromo-phenol 
• 434-64-0 perfluorotoluene 

Downstream Products

• 1610422-59-7 3-ethoxy-6,7-dihydro-9-(4-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenoxy)phenyl)-5H-benzocycloheptene 
• 1610422-68-8 3-ethoxy-6,7-dihydro-8-phenyl-9-(4-hydroxyphenyl)-5H-benzocycloheptene 
• 1610422-65-5 3-ethoxy-6,7-dihydro-8-phenyl-9-(4-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenoxy)phenyl)-5H-benzocycloheptene 
• 1610422-62-2 3-ethoxy-6,7-dihydro-8-bromo-9-(4-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenoxy)phenyl)-5H-benzocycloheptene 
• 97819-10-8 Z-1-(4-<2,5,6-trifluoro-3,4-bis(trifluoromethyl)phenoxy>phenyl)-1,2-diphenyl-1-butene 
• 97818-88-7 E-1,2-diphenyl-1-<4-<2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenoxy>phenyl>-1-butene 
• 97818-87-6 Z-1,2-diphenyl-1-<4-<2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenoxy>phenyl>-1-butene 
• 97819-01-7 Z-1,2-diphenyl-1-<4-(pentafluorophenoxy)phenyl>-1-butene 

Relevant articles and documents

Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells

Tamoxifen has biologically active metabolites: 4-hydroxytamoxifen (4OHT) and endoxifen. The E-isomers are not stable in solution as Z-isomerization occurs. We have synthesized fixed ring (FR) analogues of 4OHT and endoxifen as well as FR E and Z isomers with methoxy and ethoxy side chains. Pharmacologic properties were documented in the MCF-7 cell line, and prolactin synthesis was assessed in GH3 rat pituitary tumor cells. The FR Z-isomers of 4OHT and endoxifen were equivalent to 4OHT and endoxifen. Other test compounds used possessed partial estrogenic activity. The E-isomers of FR 4OHT and endoxifen had no estrogenic activity at therapeutic serum concentrations. None of the newly synthesized compounds were able to down-regulate ER levels. Molecular modeling demonstrated that some compounds would each create a best fit with a novel agonist conformation of the ER. The results demonstrate modulation by the ER complex of cell replication or gene transcription in cancer.